share_log

B. Riley Securities Downgrades Infinity Pharmaceuticals to Neutral, Lowers Price Target to $1.5

B. Riley Securities Downgrades Infinity Pharmaceuticals to Neutral, Lowers Price Target to $1.5

B.莱利证券将无限制药评级下调至中性,将目标价下调至1.5美元
Benzinga Real-time News ·  2022/11/16 21:04

B. Riley Securities analyst Kalpit Patel downgrades Infinity Pharmaceuticals (NASDAQ:INFI) from Buy to Neutral and lowers the price target from $3 to $1.5.

B.莱利证券分析师卡尔皮特·帕特尔将无限制药(纳斯达克:INFI)的评级从买入下调至中性,并将目标价从3美元下调至1.5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发